Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.

CEO

Dr. Mads Daugaard Ph.D.

Country

Canada

Listings

0 Comments

Share your thoughts

FAQ

What is Rakovina Therapeutics stock price today?▼

The current price of RKVTD is $0.41 USD — it has increased by +0% in the past 24 hours. Watch Rakovina Therapeutics stock price performance more closely on the chart.

What is Rakovina Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Rakovina Therapeutics stocks are traded under the ticker RKVTD.

What is Rakovina Therapeutics revenue for the last year?▼

Rakovina Therapeutics revenue for the last year amounts to 0 USD.

What is Rakovina Therapeutics net income for the last year?▼

RKVTD net income for the last year is -2.94M USD.

In which sector is Rakovina Therapeutics located?▼

Rakovina Therapeutics operates in the Health & Wellness sector.

When did Rakovina Therapeutics complete a stock split?▼

Rakovina Therapeutics has not had any recent stock splits.

Where is Rakovina Therapeutics headquartered?▼

Rakovina Therapeutics is headquartered in Vancouver, Canada.